Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hepatobiliary Pancreat Dis Int. 2010 Dec;9(6):658-60.
The 2009 H1N1 influenza A virus was first identified in April 2009 and rapidly evolved into a pandemic. Recipients of solid-organ transplants have a higher risk for severe infection because of immunosuppression. There are limited reports of 2009 H1N1 influenza in liver transplant recipients, especially in China.
We present a case of a 48-year-old male liver transplant recipient with 2009 H1N1 influenza A virus. He received therapy for acute rejection after transplantation and was confirmed with H1N1 virus infection.
The patient was started on oseltamivir (75 mg, orally twice daily) and had a benign hospital course, with defervescence and resolution of symptoms within 72 hours. The follow-up chest radiograph after discharge was normal.
The 2009 H1N1 influenza in this hospitalized transplant recipient was relatively mild, and prolonged viral shedding was not noted. Oseltamivir can be a valid measure in immunocompromised individuals.
2009 年甲型 H1N1 流感病毒于 2009 年 4 月首次被发现，并迅速演变为大流行。由于免疫抑制，实体器官移植受者发生严重感染的风险更高。有关肝移植受者感染 2009 年甲型 H1N1 流感的报道很少，特别是在中国。
我们报告了一例 48 岁男性肝移植受者感染 2009 年甲型 H1N1 流感病毒的病例。他在移植后接受了急性排斥反应的治疗，并被确诊为 H1N1 病毒感染。
该患者开始接受奥司他韦（75 mg，口服，每日 2 次）治疗，在医院的病程良好，72 小时内退热并症状缓解。出院后随访的胸部 X 线片正常。
该住院移植受者感染的 2009 年甲型 H1N1 流感相对较轻，未出现病毒持续排出。奥司他韦可能是免疫功能低下者的有效治疗措施。
